**Senior Scientist, Cancer Immunotherapy (NK Group)**
**Job Code 250RB**

**Description**
Fate Therapeutics is seeking a highly motivated immunologist to join our rapidly growing cancer immunotherapy team in the development of novel NK cell therapeutics. The position of Senior Scientist, Cancer Immunotherapy will provide scientific and technical leadership contributing to the development and characterization of novel immunotherapies from discovery stage through product development. In addition to performing, optimizing, and analyzing experiments and data involving NK and T cell characterization and function, the successful candidate will be able to lead project teams and nonclinical development of NK cell candidate programs. In addition, this role will provide subject matter expertise and direction to regulatory, process development, and clinical teams.

The qualified candidate is a motivated, interactive, and creative scientist with a track record of successful and independent laboratory investigation. Previous industry experience is preferred. Previous leadership or management experience is highly desired, as is experience and success working in and leading in cross-functional and collaborative scientific environment. An ideal candidate would possess experience characterizing immune cells through cell activation and cytotoxicity assays, cytokine profiling, multi-color flow cytometry analysis including intracellular staining, and in vivo models, with a preference for experience with in vivo xenograft models. This position reports to the Associate Director, Cancer Immunotherapy and is located at our corporate headquarters in San Diego, California.

**Responsibilities:**
- Lead a team of Scientists, Associate Scientists, and/or Research Associates to develop candidate NK cell therapeutic programs
- Provide scientific and technical expertise to advance and evaluate preclinical development of NK cell immunotherapeutic candidates.
- Design, execution, and analysis of in vitro and in vivo experiments of NK cell function
- Identify and evaluate novel approaches to modulate NK cell and T cell differentiation and effector function
- Provide scientific insight and maintain effective communication with internal research teams and external collaborators

**Qualifications**
- Ph.D. in Immunology, Cancer Biology, Cell Biology or other related field with 5+ years of relevant post-PhD experience. Previous industry experience preferred.
- Expertise in multi-parameter flow cytometry, including analysis and intracellular staining, and in vitro functional T cell and NK cell assays
- Experience developing and implementing in vivo tumor and immune-oncology models, with a preference for xenograft cancer models.
- A track record of independent scientific achievement and problem solving as demonstrated through publication
- Effective team building and teamwork skills with the ability to interact with and manage project teams, outside collaborators and commercial vendors

- Ability to prioritize and manage time efficiently

**Working Conditions and Physical Requirements**

- Will require working with cells and cell lines of human and/or animal origin
- Occasional weekend and/or evening hours required
- 100% on-site work at corporate headquarters in San Diego, CA

The preceding job description indicates the general nature and level of work performed by employees within this classification. Additional and incidental duties related to the primary duties may be required from time to time.

For consideration send cover letter and resume to: careers@fatetherapeutics.com and reference job code 250RB.

**About Fate Therapeutics, Inc.**

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company is pioneering the development of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company's immuno-oncology pipeline is comprised of NK cell and T-cell cancer immunotherapies, with a focus on developing universal, off-the-shelf cell products intended to synergize with checkpoint inhibitor and monoclonal antibody therapies and to target tumor-associated antigens. The Company's first iPSC-derived NK cell product candidates include FT500, which is currently being clinically investigated for the treatment of advanced solid tumors, and FT516, for which the Company is preparing to initiate clinical investigation for the treatment of certain hematologic malignancies. The Company's immuno-regulatory pipeline includes ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.